Wall Street brokerages predict that La Jolla Pharmaceutical (NASDAQ:LJPC) will announce earnings per share (EPS) of ($1.07) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for La Jolla Pharmaceutical’s earnings, with estimates ranging from ($1.09) to ($1.03). La Jolla Pharmaceutical reported earnings per share of ($1.93) during the same quarter last year, which would suggest a positive year over year growth rate of 44.6%. The firm is scheduled to report its next quarterly earnings results on Wednesday, October 23rd.
According to Zacks, analysts expect that La Jolla Pharmaceutical will report full year earnings of ($4.39) per share for the current financial year, with EPS estimates ranging from ($4.50) to ($4.23). For the next financial year, analysts forecast that the business will report earnings of ($2.94) per share, with EPS estimates ranging from ($3.46) to ($2.53). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow La Jolla Pharmaceutical.
La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.12). La Jolla Pharmaceutical had a negative return on equity of 715.12% and a negative net margin of 891.53%. The company had revenue of $5.70 million during the quarter, compared to analysts’ expectations of $5.76 million.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its stake in La Jolla Pharmaceutical by 3.3% during the 1st quarter. FMR LLC now owns 4,061,425 shares of the biopharmaceutical company’s stock worth $26,115,000 after acquiring an additional 128,074 shares in the last quarter. Sio Capital Management LLC acquired a new position in La Jolla Pharmaceutical during the 2nd quarter worth about $12,121,000. VHCP Management III LLC lifted its stake in La Jolla Pharmaceutical by 24.7% during the 2nd quarter. VHCP Management III LLC now owns 1,251,898 shares of the biopharmaceutical company’s stock worth $11,580,000 after acquiring an additional 248,298 shares in the last quarter. Vanguard Group Inc. lifted its stake in La Jolla Pharmaceutical by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,045,292 shares of the biopharmaceutical company’s stock worth $9,669,000 after acquiring an additional 12,097 shares in the last quarter. Finally, Boxer Capital LLC acquired a new position in La Jolla Pharmaceutical during the 2nd quarter worth about $5,319,000.
Shares of La Jolla Pharmaceutical stock traded up $0.09 during trading hours on Monday, hitting $8.54. The company’s stock had a trading volume of 5,566 shares, compared to its average volume of 289,319. La Jolla Pharmaceutical has a twelve month low of $5.01 and a twelve month high of $18.04. The firm has a fifty day moving average of $9.47 and a 200-day moving average of $8.53. The stock has a market cap of $231.78 million, a price-to-earnings ratio of -1.09 and a beta of 2.14.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
Read More: Understanding Market Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.